drugset / Trial / NCT00404248
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
Phase 1/2
Completed
35 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy, such as tetra-O-methyl nordihydroguaiaretic acid (EM-1421), work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I/II trial is studying the side effects and best dose of EM-1421 and to see how well it works in treating patients with recurrent high-grade glioma.
Timeline
- Start
- 2007-01
- Primary completion
- 2009-06
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Terameprocol | Small molecule | 750 mg | Intravenous |
| Comparator | Terameprocol | Small molecule | 1100 mg | Intravenous |
| Comparator | Terameprocol | Small molecule | 1700 mg | Intravenous |
| Comparator | Terameprocol | Small molecule | 2200 mg | Intravenous |
| Comparator | Terameprocol | Small molecule | 3000 mg | Intravenous |
| Comparator | Terameprocol | Small molecule | 4000 mg | Intravenous |
| Comparator | Terameprocol | Small molecule | 5300 mg | Intravenous |
| Comparator | Terameprocol | Small molecule | 7000 mg | Intravenous |
| Comparator | Terameprocol | Small molecule | 9300 mg | Intravenous |